Novocure Ltd Ord Sh (NVCR)

$17.01 -0.45 (-2.58%)
Market Cap 2.02B
Revenue (ttm) 655.35M
Net Income (ttm) -136.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -20.79%
Debt to Equity Ratio 0.71
Volume 994,700
Avg Vol 1,474,166
Day's Range N/A - N/A
Shares Out 115.82M
Stochastic %K 32%
Beta 0.90
Analysts Strong Sell
Price Target $25.50

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, p...

Industry: Medical Devices
Sector: Healthcare
Address:
Neuhofstrasse 21, Baar, Switzerland
trenddetector
trenddetector May. 19 at 4:48 PM
$NVCR Optune Pax just received FDA approval for locally advanced pancreatic cancer — the first approved therapy specific to this indication in nearly 30 years. Tumor Treating Fields now validated in PDAC. Full breakdown live at YourCancerPath.com/pancreatic-cancer #Novocure #PancreaticCancer
1 · Reply
scotofool
scotofool May. 19 at 3:45 AM
$NVCR mates medussa tekkfakky datas swiggard ceo proper cock-up target 7.
0 · Reply
Tdorsey1776
Tdorsey1776 May. 18 at 2:43 PM
$NVCR Fantastic relative strength. Shorts sneaking out without too much damage
0 · Reply
Tdorsey1776
Tdorsey1776 May. 15 at 5:52 PM
$CADL $NVCR $VRDN Candel moves up the M&A list on prostate alone based on the investor call today. Go listen, someone writes a big check for these guys. I added...again. I just hope for a selloff to buy in real size. GLTA
3 · Reply
Czm514
Czm514 May. 15 at 3:32 PM
$IBRX $NVCR Could we see a follow up on this study soon? Whatever became of this press release back in August 2025? “Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device”. How are these patients doing today?
0 · Reply
Keendawg
Keendawg May. 14 at 3:55 PM
$NVCR strength
0 · Reply
EVZ
EVZ May. 14 at 1:47 PM
$OMER Dogpoop stock! The early run to 15 was a trap for the longs to hold until earnings. Sell the news! This will not cross 20 this year. In hindsight, should have dumped this for $NVCR
2 · Reply
Tdorsey1776
Tdorsey1776 May. 13 at 2:24 PM
$NVCR Not enough sell pressure to knock this down, looks like it will continue to grind higher as the shorts cover and perhaps we are seeing some new buying. Risk/reward still strong IMO. GLTA
1 · Reply
CCrazy1990
CCrazy1990 May. 12 at 9:32 PM
$NVCR now FDA Commissioner pushed out. What an absolute cluster F DHHS and its “leader” are. This is what happens when you hire lackeys over competent people for critical positions like Sec of DHHS.
1 · Reply
CCrazy1990
CCrazy1990 May. 12 at 8:41 PM
$NVCR shares short went from 8.71M on April 16 to 6.97M on April 30 (the day Q1 earnings release dropped)
0 · Reply
Latest News on NVCR
Novocure price target raised to $17 from $13.50 at Wells Fargo

2026-05-04T10:36:48.000Z - 15 days ago

Novocure price target raised to $17 from $13.50 at Wells Fargo

Novocure price target raised to $20 from $16 at Evercore ISI

2026-05-01T12:15:56.000Z - 18 days ago

Novocure price target raised to $20 from $16 at Evercore ISI

Novocure reports Q1 EPS (62c), consensus (51c)

2026-04-30T13:13:37.000Z - 19 days ago

Novocure reports Q1 EPS (62c), consensus (51c)

Novocure raises FY26 revenue view to $690M-$710M from $675M-$705M

2026-04-30T13:12:44.000Z - 19 days ago

Novocure raises FY26 revenue view to $690M-$710M from $675M-$705M

NovoCure Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 19 days ago

NovoCure Earnings Call Transcript: Q1 2026

NovoCure Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 19 days ago

NovoCure Quarterly report: Q1 2026

NovoCure Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 19 days ago

NovoCure Earnings release: Q1 2026

NovoCure Slides: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 19 days ago

NovoCure Slides: Q1 2026

Novocure Reports First Quarter 2026 Financial Results

Apr 30, 2026, 7:00 AM EDT - 19 days ago

Novocure Reports First Quarter 2026 Financial Results

NovoCure Slides: Corporate presentation

Apr 29, 2026, 7:00 AM EDT - 20 days ago

NovoCure Slides: Corporate presentation

NovoCure Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 weeks ago

NovoCure Proxy statement: Proxy filing

NovoCure Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 weeks ago

NovoCure Proxy statement: Proxy filing

Novocure price target lowered to $16 from $23 at Evercore ISI

2026-04-06T12:12:23.000Z - 6 weeks ago

Novocure price target lowered to $16 from $23 at Evercore ISI

Novocure to Report First Quarter 2026 Financial Results

Apr 1, 2026, 7:00 AM EDT - 6 weeks ago

Novocure to Report First Quarter 2026 Financial Results

Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint

2026-03-26T11:11:40.000Z - 7 weeks ago

Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Mar 26, 2026, 7:00 AM EDT - 7 weeks ago

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

NovoCure Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

NovoCure Transcript: Leerink Global Healthcare Conference 2026

Novocure gets reimbursement approval in Japan for Optune Lua

2026-03-02T12:33:53.000Z - 2 months ago

Novocure gets reimbursement approval in Japan for Optune Lua

Novocure gets reimbursement approval in Japan for Optune Lua

2026-03-02T12:30:14.000Z - 2 months ago

Novocure gets reimbursement approval in Japan for Optune Lua

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Mar 2, 2026, 7:00 AM EST - 2 months ago

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure to Participate in 2026 Leerink Global Healthcare Conference

Feb 27, 2026, 4:30 PM EST - 2 months ago

Novocure to Participate in 2026 Leerink Global Healthcare Conference

NovoCure Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

NovoCure Earnings Call Transcript: Q4 2025

NovoCure Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

NovoCure Annual report: Q4 2025

NovoCure Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

NovoCure Earnings release: Q4 2025

NovoCure Slides: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

NovoCure Slides: Q4 2025

Novocure reports Q4 EPS (22c), consensus (41c)

2026-02-26T12:36:11.000Z - 2 months ago

Novocure reports Q4 EPS (22c), consensus (41c)

Novocure sees FY26 revenue $675M-$705M, consensus $681.24M

2026-02-26T12:35:04.000Z - 2 months ago

Novocure sees FY26 revenue $675M-$705M, consensus $681.24M

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Feb 26, 2026, 7:00 AM EST - 2 months ago

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Novocure says CMS rescinds revocation of billing privileges

2026-02-25T14:00:43.000Z - 2 months ago

Novocure says CMS rescinds revocation of billing privileges

Novocure jumps 11% after CMS reinstates Medicare billing privileges

2026-02-25T13:59:52.000Z - 2 months ago

Novocure jumps 11% after CMS reinstates Medicare billing privileges

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

Feb 24, 2026, 7:00 AM EST - 3 months ago

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

Unusually active option classes on open February 12th

2026-02-12T14:40:28.000Z - 3 months ago

Unusually active option classes on open February 12th

BP CROX FDX LVS MU SGHC TZA

Why Is NovoCure Stock (NVCR) Up Today?

2026-02-12T13:09:04.000Z - 3 months ago

Why Is NovoCure Stock (NVCR) Up Today?

This Biotech Stock Is Jumping 25% After Getting an FDA Boost

Feb 12, 2026, 6:53 AM EST - 3 months ago

This Biotech Stock Is Jumping 25% After Getting an FDA Boost

What's Happening With NovoCure Stock?

Feb 12, 2026, 6:15 AM EST - 3 months ago

What's Happening With NovoCure Stock?

Novocure price target raised to $47 from $39 at H.C. Wainwright

2026-02-12T11:05:11.000Z - 3 months ago

Novocure price target raised to $47 from $39 at H.C. Wainwright

Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar

Feb 11, 2026, 6:33 PM EST - 3 months ago

Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar

Novocure’s Optune Pax approved by FDA to treat pancreatic cancer

2026-02-11T23:00:22.000Z - 3 months ago

Novocure’s Optune Pax approved by FDA to treat pancreatic cancer

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Feb 11, 2026, 5:54 PM EST - 3 months ago

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

NovoCure Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:45 PM EST - 4 months ago

NovoCure Transcript: 44th Annual J.P. Morgan Healthcare Conference

NovoCure Slides: Corporate presentation

Jan 13, 2026, 7:00 AM EST - 4 months ago

NovoCure Slides: Corporate presentation

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Jan 12, 2026, 7:00 AM EST - 4 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 7:00 AM EST - 5 months ago

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

NovoCure Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 11:30 AM EST - 6 months ago

NovoCure Transcript: Piper Sandler 37th Annual Healthcare Conference

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Dec 1, 2025, 7:00 AM EST - 6 months ago

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 6 months ago

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

NovoCure Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 9:00 AM EST - 6 months ago

NovoCure Transcript: Jefferies London Healthcare Conference 2025

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Nov 12, 2025, 7:00 AM EST - 6 months ago

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

NovoCure Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

NovoCure Earnings Call Transcript: Q3 2025

NovoCure Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

NovoCure Quarterly report: Q3 2025

NovoCure Earnings release: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

NovoCure Earnings release: Q3 2025

NovoCure Slides: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

NovoCure Slides: Q3 2025

Novocure Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:00 AM EDT - 7 months ago

Novocure Reports Third Quarter 2025 Financial Results

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Oct 15, 2025, 7:00 AM EDT - 7 months ago

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Novocure to Report Third Quarter 2025 Financial Results

Oct 1, 2025, 7:00 AM EDT - 8 months ago

Novocure to Report Third Quarter 2025 Financial Results

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Sep 29, 2025, 4:30 PM EDT - 8 months ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sep 15, 2025, 7:00 AM EDT - 8 months ago

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

NovoCure Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 3:20 PM EDT - 8 months ago

NovoCure Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

NovoCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 2:00 PM EDT - 9 months ago

NovoCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

NovoCure Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 9:30 AM EDT - 9 months ago

NovoCure Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Novocure Announces Upcoming Investor Events

Aug 28, 2025, 7:00 AM EDT - 9 months ago

Novocure Announces Upcoming Investor Events

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Aug 25, 2025, 7:00 AM EDT - 9 months ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Aug 20, 2025, 7:00 AM EDT - 9 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

NovoCure Earnings Call Transcript: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 10 months ago

NovoCure Earnings Call Transcript: Q2 2025

NovoCure Earnings release: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 10 months ago

NovoCure Earnings release: Q2 2025

NovoCure Quarterly report: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 10 months ago

NovoCure Quarterly report: Q2 2025

NovoCure Slides: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 10 months ago

NovoCure Slides: Q2 2025

Novocure Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:00 AM EDT - 10 months ago

Novocure Reports Second Quarter 2025 Financial Results

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Jul 1, 2025, 7:00 AM EDT - 11 months ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Novocure to Report Second Quarter 2025 Financial Results

Jun 30, 2025, 7:00 AM EDT - 11 months ago

Novocure to Report Second Quarter 2025 Financial Results

NovoCure Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 12:50 PM EDT - 1 year ago

NovoCure Transcript: Jefferies Global Healthcare Conference 2025

NovoCure Slides: Corporate Presentation

Jun 3, 2025, 7:00 AM EDT - 1 year ago

NovoCure Slides: Corporate Presentation

NovoCure Transcript: Study Result

May 31, 2025, 8:01 PM EDT - 1 year ago

NovoCure Transcript: Study Result

NovoCure Press release: Study Result

May 31, 2025, 8:01 PM EDT - 1 year ago

NovoCure Press release: Study Result

NovoCure Slides: Study Result

May 31, 2025, 8:01 PM EDT - 1 year ago

NovoCure Slides: Study Result

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 1 year ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

ZLAB

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 8:00 AM EDT - 1 year ago

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NovoCure Earnings Call Transcript: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q1 2025

NovoCure Earnings release: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Earnings release: Q1 2025

NovoCure Quarterly report: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Quarterly report: Q1 2025

NovoCure Slides: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Slides: Q1 2025

Novocure Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Novocure Reports First Quarter 2025 Financial Results

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 10:16 AM EDT - 1 year ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Apr 22, 2025, 7:09 AM EDT - 1 year ago

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

NovoCure Proxy statement: Proxy Filing

NovoCure Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

NovoCure Proxy statement: Proxy Filing

Novocure to Report First Quarter 2025 Financial Results

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Novocure to Report First Quarter 2025 Financial Results

NovoCure Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 4:20 PM EDT - 1 year ago

NovoCure Transcript: Leerink’s Global Healthcare Conference 2025

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

NovoCure Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Earnings Call Transcript: Q4 2024

NovoCure Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Earnings release: Q4 2024

NovoCure Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Annual report: Q4 2024

NovoCure Slides: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Slides: Q4 2024

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 22, 2025, 4:00 AM EST - 1 year ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

NovoCure Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 12:00 PM EST - 1 year ago

NovoCure Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 13, 2025, 7:00 AM EST - 1 year ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

NovoCure Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 12:00 PM EST - 1 year ago

NovoCure Transcript: Piper Sandler 36th Annual Healthcare Conference

NovoCure Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 4, 2024, 2:10 PM EST - 1 year ago

NovoCure Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Dec 2, 2024, 7:17 AM EST - 1 year ago

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Dec 2, 2024, 7:02 AM EST - 1 year ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

ZLAB

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Dec 2, 2024, 7:00 AM EST - 1 year ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 1 year ago

Novocure to Participate in Upcoming Investor Conferences

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Nov 21, 2024, 7:05 AM EST - 1 year ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Nov 21, 2024, 7:00 AM EST - 1 year ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

NovoCure Earnings Call Transcript: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q3 2024

NovoCure Earnings release: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Earnings release: Q3 2024

NovoCure Quarterly report: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Quarterly report: Q3 2024

NovoCure Slides: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Slides: Q3 2024

NovoCure Slides: Corporate Presentation

Oct 30, 2024, 7:30 AM EDT - 1 year ago

NovoCure Slides: Corporate Presentation

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Oct 30, 2024, 7:02 AM EDT - 1 year ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Novocure Reports Third Quarter 2024 Financial Results

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Novocure Reports Third Quarter 2024 Financial Results

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Oct 15, 2024, 4:43 PM EDT - 1 year ago

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Novocure to Report Third Quarter 2024 Financial Results

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Novocure to Report Third Quarter 2024 Financial Results

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

NovoCure Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 4:30 PM EDT - 1 year ago

NovoCure Transcript: 2024 Wells Fargo Healthcare Conference

Novocure Announces Planned CEO Transition

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Novocure Announces Planned CEO Transition

trenddetector
trenddetector May. 19 at 4:48 PM
$NVCR Optune Pax just received FDA approval for locally advanced pancreatic cancer — the first approved therapy specific to this indication in nearly 30 years. Tumor Treating Fields now validated in PDAC. Full breakdown live at YourCancerPath.com/pancreatic-cancer #Novocure #PancreaticCancer
1 · Reply
scotofool
scotofool May. 19 at 3:45 AM
$NVCR mates medussa tekkfakky datas swiggard ceo proper cock-up target 7.
0 · Reply
Tdorsey1776
Tdorsey1776 May. 18 at 2:43 PM
$NVCR Fantastic relative strength. Shorts sneaking out without too much damage
0 · Reply
Tdorsey1776
Tdorsey1776 May. 15 at 5:52 PM
$CADL $NVCR $VRDN Candel moves up the M&A list on prostate alone based on the investor call today. Go listen, someone writes a big check for these guys. I added...again. I just hope for a selloff to buy in real size. GLTA
3 · Reply
Czm514
Czm514 May. 15 at 3:32 PM
$IBRX $NVCR Could we see a follow up on this study soon? Whatever became of this press release back in August 2025? “Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device”. How are these patients doing today?
0 · Reply
Keendawg
Keendawg May. 14 at 3:55 PM
$NVCR strength
0 · Reply
EVZ
EVZ May. 14 at 1:47 PM
$OMER Dogpoop stock! The early run to 15 was a trap for the longs to hold until earnings. Sell the news! This will not cross 20 this year. In hindsight, should have dumped this for $NVCR
2 · Reply
Tdorsey1776
Tdorsey1776 May. 13 at 2:24 PM
$NVCR Not enough sell pressure to knock this down, looks like it will continue to grind higher as the shorts cover and perhaps we are seeing some new buying. Risk/reward still strong IMO. GLTA
1 · Reply
CCrazy1990
CCrazy1990 May. 12 at 9:32 PM
$NVCR now FDA Commissioner pushed out. What an absolute cluster F DHHS and its “leader” are. This is what happens when you hire lackeys over competent people for critical positions like Sec of DHHS.
1 · Reply
CCrazy1990
CCrazy1990 May. 12 at 8:41 PM
$NVCR shares short went from 8.71M on April 16 to 6.97M on April 30 (the day Q1 earnings release dropped)
0 · Reply
Stonkapedia
Stonkapedia May. 12 at 8:20 PM
$NVCR awww look at this POS go 💩
0 · Reply
Tdorsey1776
Tdorsey1776 May. 12 at 5:15 PM
$NVCR https://seekingalpha.com/article/4859323-why-novocure-is-failing-to-disrupt-nsclc
0 · Reply
Tdorsey1776
Tdorsey1776 May. 12 at 5:13 PM
$NVCR Shorts and naysayers...don't let the door hit you in the azzzzzz on the way out
1 · Reply
Tdorsey1776
Tdorsey1776 May. 11 at 2:27 PM
$VRDN $NVCR
2 · Reply
Tdorsey1776
Tdorsey1776 May. 11 at 1:40 PM
$NVCR Shorts still trying to sneak out the back door.....
2 · Reply
scotofool
scotofool May. 11 at 10:13 AM
$NVCR mates dungeondwellas show smileys.Yet wanker ceo lyes no userdoccies panky fakky datas. $NVCR proper trash, target 7
1 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN May. 9 at 12:09 AM
$NVCR filing after the close. Apparently, Soleus Capital has been buying. In Q1'26, appears that Soleus added almost 2M shares. Now owns 10.49M shares, or 9.1%.
5 · Reply
BB_88_
BB_88_ May. 8 at 11:33 PM
$S $NVCR had these both at all time lows fml didn’t hold
0 · Reply
CCrazy1990
CCrazy1990 May. 8 at 8:06 PM
$NVCR another good week. See you fellow degenerates on Monday!
0 · Reply
BB_88_
BB_88_ May. 8 at 6:38 PM
$NVCR covered
0 · Reply
BB_88_
BB_88_ May. 8 at 6:26 PM
$NVCR as expected crack
0 · Reply
BB_88_
BB_88_ May. 8 at 6:01 PM
$NVCR here is the crack back to 16. Listen I’m bullish I had buys at 9 and 10 never held :(
0 · Reply